Tsarin Halittar Halittar Dan Adam na CYP2C9 da VKORC1

Warfarin magani ne na hana zubar jini ta baki wanda aka fi amfani da shi a asibiti a halin yanzu, wanda aka yi niyya musamman don rigakafi da maganin cututtukan thromboembolic. Duk da haka, warfarin yana da iyakataccen lokacin magani kuma ya bambanta sosai tsakanin jinsi daban-daban da mutane. Kididdiga ta nuna cewa bambancin yawan shan magani a cikin mutane daban-daban na iya zama fiye da sau 20. Zubar da jini mai kyau yana faruwa a cikin kashi 15.2% na marasa lafiya da ke shan warfarin kowace shekara, wanda kashi 3.5% ke haifar da zubar jini mai kisa. Nazarin magunguna ya nuna cewa yawan kwayoyin halitta na enzyme VKORC1 da enzyme na rayuwa CYP2C9 na warfarin muhimmin abu ne da ke shafar bambancin yawan maganin warfarin. Warfarin wani takamaiman mai hana sinadarin bitamin K epoxide reductase (VKORC1), don haka yana hana hada sinadarin coagulation wanda ya shafi bitamin K kuma yana samar da maganin hana zubar jini. Yawancin bincike sun nuna cewa yawan kwayar halittar VKORC1 mai haɓaka VKORC1 shine mafi mahimmancin abin da ke shafar bambancin launin fata da na mutum a cikin adadin da ake buƙata na warfarin. CYP2C9 yana samar da warfarin, kuma maye gurbi yana rage saurin metabolism na warfarin. Mutanen da ke amfani da warfarin suna da haɗarin zubar jini mafi girma (sau biyu zuwa uku fiye da haka) a farkon matakin amfani.